Lipoprotein profile in patients who survive a stroke

Neuroendocrinology Letters

Volumn 32, Issue 4, 2011, Pages 496-501

  Oravec, Stanislav ^a   Krivošíková, Zuzana ^a   Krivošík, Marek ^b   Gruber, Kristina ^c   Gruber, Michael ^c   Dukát, Andrej ^a   Gavorník, Peter ^a  

^a Bratislava   (Slovakia)

^b Derer 's University Hospital Slovakia   (Slovakia)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atherogenic vs. non aterhogenic lipoprotein phenotype; LDL subpopulations; Small dense LDL; Stroke

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; RISK ASSESSMENT; STROKE; SURVIVOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 80053606154     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Adams HP, Benedixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE (1993) Classification of subtype of acute ischemic stroke. Definition for use in a multicenter clinical trial. TOAST Trial of Org 10172 in Acute Stroke Treatment. Stroke. 24(1): 35-41. (Pubitemid 23014379)
2. Amarenco P, Labreuche J, Touboul PJ (2008) High-density lipoprotein cholesterol and risk of stroke and karotid atherosklerosis. A systemic review. Atherosclerosis. 196 (2): 489-496. (Pubitemid 351146660)
3. Amarenco P, Bogusslavsky J, Caplan LR, Donnan GA, Hennerici MG (2009) Classification of Stroke Subtypes. Cerebrovasc Dis. 27(5): 493-501.
4. Backers J (2005) Effect of Lipid-Lowering Drug Therapy on Small-dense Low-Density Lipoprotein. Ann Pharmacol. 39(3): 523-526.
5. Bejot Y, Benatru I, Rouaud O, Fromont A, Besancenot JP, Moreau T, Giroud M (2007) Epidemiology of stroke in Europe: Geographic and enviromenal differences. J Neurol Sci. 262(1-2): 85-88. (Pubitemid 47390898)
6. Berneis KK, Kraus RM (2002) Meabolic origins and clinical significance of LDL Heterogeneity. J Lipid Res 43(9): 1363-1379.
7. Bulas J (2006) Interdisciplinárny prístup k liečbe náhlej cievnej mozgovej príhody zo strany internistu [(A complex approach to the treatment of an acute cerebral-vascular event from the position of internist) (In Slovak)] Interná med. 6(9): 1363-1379.
8. Chun Xia Zhao, Ying Hua Cui, Qiao Fan, Pei Hua Wang, Ruitai Hui, Cianflone K, Dao Wen Wang (2009) Small Dense Low-Density Lipoproteins and Associated Risk Factors in Patients with Stroke. Cerebrovasc Dis. 27(1): 99-104.
9. Fruchart JC, Sacks FM, Hermans MP et al (2008) The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diabetes Vasc. Res. 5(4): 319-335.
10. Hoefner DM, Hodel SD, O'Brien JF, Branum EL, Sun D, Meissner I, McConnell JP (2001) Development of a rapid quantitative method for LDL subfraction with use of the Quantimetrix Lipoprint LDL system. Clin Chem. 47(2): 266-274. (Pubitemid 32142925)
11. Kalita Z (2006) Akutní cévní mozkové příhody. Diagnostika, patofyziologie, mamagement. (The acute cerebral-vascular events. Diagnostics, pathophysiology, management) Maxdorf, Praha, 623p.
12. Oravec S (2006): Identifikácia subpopulácií LDL triedy - Aktuálny prínos v diagnostike porúch metabolizmu lipoproteínov a ochorení kardiovaskulárneho systému (Identification of subfractions in LDL family - an actual contribution in the diagnostics of disturbances of lipoprotein metabolism and cardiovascular system diseases) Med Milit Slov. 8(1): 32-34.
13. Oravec S (2007a) Nové perspektívy v diagnostike porúch metabolizmu lipoproteinov - prínos v interpretácii výsledkov (New perspectives in the diagnostics of lipoprotein metabolism disturbances - a contribution in the interpretation of results. Med Milit Slov. 9(1): 42-45.
14. Oravec S (2007b) Nové možnosti posúdenia kardiovaskulárneho rizika u pacientov s obezitou a metabolickými ochoreniami (A new judgement of cardiovascular risk in obese patients and in patients with metabolic disturbances) Med Milit Slov 9(1): 46-49.
15. Oravec S (2010) Den drohenden Herztod erkennen - und vermeiden. Der Mediziner. 19(4): 6-7.
16. Oravec S, Dukat A, Gavorník P, Caprnda M, Kucera M (2010a) Lipoproteínový profil séra pri novozistenej arteriálnej hypertenzii. Úloha aterogénnych lipoproteínov v patogenéze ochorenia. (The serum lipoprotein profile in newly diagnozed arterial hypertension. A role of atherogenic lipoproteins in the pathogenesis of illness) Vnitr Lek. 56(9): 967-971.
17. Oravec S., Dukát A., Gavorník P., Čaprnda M, Reinoldová O (2010b) Zmeny v lipoproteínovom spektre pri končatinovocievnej ischemickej chorobe. Vnitř. Lék. 56(6): 620-623.
18. Oravec S, Dukat A, Gavornok P, Caprnda M, Kucera M, Ocadlik I (2011) Contribution of the atherogenic lipoprotein profile to the development of arterial hypertension. Brat Lek Listy. 112(1): 4-7.
19. Packard CJ (2003) Triacylglycerol-rich lipoproteins and the generation of small dense low-density lipoprotein. Biochem Soc Trans. 31(5): 1066-1069.
20. Rubins HB, Davenport J, Babikian V et al (2001) Reduction in stroke with gemfibrozil in menwith coronary heart disease and low HDL cholesterol: the veterans affairs HDL intervention trial (VA-HIT) Circulation. 103(23): 2828-2833. (Pubitemid 32550072)
21. Sarkar PD, Rautaray SS (2008) Oxidized LDL and Paraoxonase status in ischemic stroke patients. Indian J Physiol Prarmacol. 52(4): 403-407.
22. Shoji T, Hatsuda S, Tsuchikura S, Shinohara K, Komoto E, Kovama H, Emoto M, Nishizhawa Y (2009) Small dense low-density lipoprotein cholesterol concentration and carotid atherosclerosis. Atheroscler. 202(2): 582-588.
23. Tanne D, Koren-Morgan N, Graff E, Goldbourt U (2001) Blood lipids and first ever Ischemic stroke, transient ischemic attack in the bezafibrate infarction prevention (BIP) registry: High triglyceride constitute an independent risk factor. Circulation. 104(24): 2892-97. (Pubitemid 33139099)
24. van J, Pan J, Charles MA, Krauss R, Wong N, Wu X (2007) Atherogenic lipid phenotype in a general group of subjects. Arch Pathol Lab Med. 131(11): 1679-1685. (Pubitemid 350077465)
25. Vrablik M (2009) Prevence cévnich mozkových příhod hypolipidemickou léčbou. Remedia: internetové stránky českého farmakoterapeutického dvouměsičníku, rubrika PND duben 2, 2009 (The prevention of stroke by hypolipidemic treatment. Remedia. Internet Website of Czech Farmacotherapeutical two-monthly Journal, Rubric PND, April 2nd, 2009).